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ABSTRACT
Background Municipal drinking water contaminated 
with perfluorinated alkyl acids had been distributed to 
one-third of households in Ronneby, Sweden. The source 
was firefighting foam used in a nearby airfield since the 
mid-1980s. Clean water was provided from 16 December 
2013.
Objective To determine the rates of decline in serum 
perfluorohexane sulfonate (PFHxS), perfluorooctane 
sulfonate (PFOS) and perfluorooctanoate (PFOA), and 
their corresponding half-lives.
Methods Up to seven blood samples were collected 
between June 2014 and September 2016 from 106 
participants (age 4–84 years, 53% female).
Results Median initial serum concentrations were 
PFHxS, 277 ng/mL (range 12–1660); PFOS, 345 ng/mL 
(range 24–1500); and PFOA, 18 ng/mL (range 2.4–92). 
The covariate-adjusted average rates of decrease in 
serum were PFHxS, 13% per year (95% CI 12% to 15%); 
PFOS, 20% per year (95% CI 19% to 22%); and PFOA, 
26% per year (95% CI 24% to 28%). The observed 
data are consistent with a first-order elimination model. 
The mean estimated half-life was 5.3 years (95% CI 
4.6 to 6.0) for PFHxS, 3.4 years (95% CI 3.1 to 3.7) for 
PFOS and 2.7 years (95% CI 2.5 to 2.9) for PFOA. The 
interindividual variation of half-life was around threefold 
when comparing the 5th and 95th percentiles. There 
was a marked sex difference with more rapid elimination 
in women for PFHxS and PFOS, but only marginally for 
PFOA.
Conclusions The estimated half-life for PFHxS was 
considerably longer than for PFOS and PFOA. For PFHxS 
and PFOS, the average half-life is shorter than the 
previously published estimates. For PFOA the half-life is 
in line with the range of published estimates.
InTROduCTIOn
Perfluorinated and polyfluorinated substances 
(PFASs) comprise a group of many different 
synthetic substances that have been produced and 
widely used for approximately 50 years. They are 
found in industrial applications and household 
products mainly due to their properties of with-
standing heat, oil, dirt and water. PFASs are also 
used as surfactants in firefighting foam of the 
aqueous film forming foam (AFFF) type.1 
In the general population, the dominating 
sources of exposure are through diet and consumer 
products.2 However, during the past decade it has 
become apparent that localised PFAS contamina-
tion to surface and groundwater occurs around 
military and civilian firefighting training facilities, 
where large quantities of AFFF foams have been 
used. These substances are further disseminated by 
means of groundwater flows, and may also reach 
drinking water wells.
PFASs are excreted via urine and faeces. In 
animals half-lives (T½) for PFASs vary markedly 
between species and are usually much shorter 
than in humans, with elimination half-life counted 
in hours or days.3 Reabsorption by organic anion 
transporters (OATs) in the kidneys and extensive 
uptake from enterohepatic circulation for PFASs 
are believed to be more active processes in humans, 
slowing down the excretion of these substances. 
In observational studies, based on observations 
in individuals followed over time, T½ between 2 
and 3 years was reported for perfluorooctanoic acid 
(PFOA), while longer half-lives for perfluorooctane 
sulfonic acid (PFOS) and perfluorohexane sulfonic 
acid (PFHxS), 4 and 7 years, respectively, have been 
observed (table 1). Time-trend general population 
studies during periods of observed decay have 
reported half-lives in similar ranges.
However, it should be noted that the interin-
dividual variation in elimination of PFASs can be 
substantial in both high and low exposure ranges, 
as observed in retired fluorochemical workers and 
after drinking water exposure.4 5 Observational 
data and pharmacokinetical modelling indicate 
that PFAS half-life is likely to be shorter in women, 
explained partly by menstrual blood losses, but 
there may also be other sex-specific elimination 
mechanisms.6 Except for perfluorobutane sulfonic 
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What this paper adds
 ► Limited information on the elimination of 
perfluorinated alkyl acids in humans after end 
of exposure has suggested half-lives of several 
years.
 ► This study provides refined estimates of half-
lives of perfluorohexane sulfonate (PFHxS) 
and perfluorooctane sulfonate (PFOS) from a 
highly exposed general population after end of 
exposure. There is substantial interindividual 
variability and slower excretion for men than 
women, for PFHxS and PFOS.
 ► Future research to understand the determinants 
of elimination is needed in order to guide 
risk assessment and regulatory measures for 
perfluorinated chemicals.
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Table 2 Perfluorinated and polyfluorinated substance levels (ng/L) 
in outgoing drinking water from the two waterworks in Ronneby, 
Sweden, on 10 December 2013
Brantafors Kärragården
Perfluoropentanoic acid 38 10
Perfluorohexanoic acid 320 3.6
Perfluoroheptanoic acid 32 1.4
Perfluorooctanoic acid 100 1.0
Perfluorononanoic acid <1 <1
Perfluorodecanoic acid <1 <1
Perfluoroundecanoic acid <10 <10
Perfluorododecanoic acid <10 <10
Perfluorobutane sulfonic acid 130 <2.6
Perfluorohexane sulfonic acid 1700 4.6
Perfluoroheptane sulfonic acid 60 <1
Perfluorooctane sulfonic acid 8000 27
Exposure assessment
acid, which has a much shorter half-life, around 1 month,7 there 
are no human data after end of exposure for other PFASs.
Ronneby: a case study from Sweden
In autumn 2013 a survey of groundwater quality in Blekinge 
county in southern Sweden showed alarmingly high levels of 
PFASs in groundwater from a glaciofluvial water reservoir, the 
Bredåkra delta, which has a military and civil airfield located 
in its centre. Extended water sampling revealed very high levels 
of PFASs in outgoing drinking water from Brantafors, one of 
the two municipal waterworks in Ronneby, a municipality with 
28 000 inhabitants (table 2). This waterworks provided drinking 
water to one-third of the households in Ronneby. The contami-
nated waterworks was closed on 16 December 2013, and clean 
water was promptly provided by Kärragården, the second water-
works in the municipality. After a few days no elevated levels of 
PFASs could be detected in the distribution network. Brantafors 
waterworks was reopened in May 2014, supplied with new coal 
filters and using water only from wells with low PFASs levels, 
but the trial was ended in October 2014. During this trial the 
levels of PFASs (sum of 11) were closely monitored, reaching at 
most 40 ng/L (ie, well below 90 ng/L, the present Swedish recom-
mended action level).
It was soon confirmed that the fire drill site at the nearby mili-
tary airport localised within the aquifer area had leached PFASs 
to the environment. Despite considerable efforts from the Armed 
Forces, it has not been possible to reconstruct the detailed histor-
ical use of AFFF at the airfield, but the best estimate as to the 
start of the use of these foams is the mid-1980s. Very little infor-
mation on past or current PFAS content in the foams used at 
the facility was available, only that PFOS-containing foams were 
not purchased since 2004. For a general overview of AFFFs, 
see refs 1 and 8.
Extensive biomonitoring in the municipality population 
started in June 2014, approximately 6 months after end of expo-
sure through drinking water, by open invitations and free of 
cost. Subjects living and working in the contaminated as well as 
in the uncontaminated district were invited. During the period 
2014–2016 a  total of 3418 persons from Ronneby partici-
pated. Considerable efforts were made to recruit persons with 
little exposure to the contaminated water, in order to ensure a 
broad range of serum PFASs levels for further research on health 
effects. A reference group of 242 subjects from a nearby unex-
posed municipality (Karlshamn) was also examined in 2016.
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Table 3 Summary statistics of PFAS concentrations (ng/mL) in 106 
participants in a panel study 6 months after end of exposure through 
contaminated drinking water (baseline investigation)
PFAS Group
Participants 
(n) Mean±Sd (Min, median, max)
PFHxS Panel study 106 353±260 (12.3, 277, 1660)
Main Ronneby 3418 228±232 (<0.5*, 152, 1790)
Karlshamn 
reference 242 1.91±5.27 (<0.5*, 0.84, 60.1)
PFOS Panel study 106 387±259 (24.1, 345, 1500)
Main Ronneby 3418 245±234 (0.58, 176, 1870)
Karlshamn 
reference 242 5.68±6.19 (<0.5*, 4.21, 55.3)
PFOA Panel study 106 21.1±14.7 (2.38, 17.5, 92)
Main Ronneby 3418 13.7±12.0 (<0.4*, 10.4, 91.9)
Karlshamn 
reference 242 1.77±0.81 (<0.4*, 1.59, 4.98)
*Limit of detection.
PFAS, perfluorinated and polyfluorinated substance; PFHxS, perfluorohexane 
sulfonate; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate. 
Exposure assessment
METHOdS
Study group
From among the first participants in the screening programme, 
volunteers were invited to participate in the half-life study until 
the target of 100 subjects, evenly split by gender, was achieved. 
The panel study group (n=106) with a large age span, 4–83 
years at baseline, was established in June 2014. The propor-
tion of women was 53%. There were 20 men aged 15–50, and 
30 women (menstruating ages). The participants have donated 
blood regularly, initially every third month, then with longer 
intervals. Analysis of PFASs in serum is performed after each 
sampling round and the individual results are immediately 
reported back to the participants.
We here report findings from the first seven sampling rounds (in 
June 2014, October 2014, January 2015, April 2015, September 
2015, March 2016 and September 2016). The median number 
of samples per person was 6. Continued sampling twice a year is 
planned for several years to come.
Chemical analysis
Plasma concentrations of PFHxS, PFOS and PFOA were analysed 
at the Department of Occupational and Environmental Medi-
cine in Lund, Sweden, using liquid chromatography-tandem 
mass spectrometry (LC/MS/MS). The samples were analysed 
according to a modified method9 and determined as the total, 
non-isomer-specific compounds. The aliquots of 25 µL serum 
were added with 75 µL of water. A solution containing labelled 
internal standards were added and the proteins were precipi-
tated using acetonitrile followed by vigorous shaking for 30 min. 
The samples were then centrifuged and 1 µL of the supernatant 
was analysed using an LC (UFLCXR, Shimadzu Corporation, 
Kyoto, Japan) connected to the MS/MS (QTRAP 5500, AB 
Sciex, Foster City, California, USA). Limits of detection deter-
mined as the concentrations corresponding to three times the SD 
of the responses in chemical blanks were 0.5 ng/mL for PFHxS 
and PFOS, and 0.4 ng/mL for PFOA. Coefficients of variation of 
quality control (QC)  samples at 100 ng/mL were 6% for PFHxS 
and PFOS, and 8% for PFOA. The analyses of PFOS and PFOA 
are part of a quality control programme between analytical labo-
ratories coordinated by Professor Hans Drexler, Institute and 
Outpatient Clinic for Occupational, Social and Environmental 
Medicine, University of Erlangen-Nuremberg, Germany.
Modelling of half-life
A linear mixed-effect model was used to assess predictors of 
subject-specific serum PFAS concentrations over time, from 
which we derive excretion rate and serum elimination half-lives 
of each PFAS. The following mixed model was used to fit the 
panel data:
In Cij = αi + tijki + Xiβ + εij,
where Cij is the serum PFAS concentrations for individual i and 
sampling round j, αi is the subject-specific intercept, tij is the 
time elapsed between the clean water was provided and the 
blood sample collection, ki is the subject-specific slope, Xi is a 
vector of fixed covariates for individual i, including age, gender 
and body mass index (BMI), β is the fixed effect coefficient and 
εij is the random error term. The subject-specific intercept αi, 
the subject-specific slope ki and the random error term εij were 
modelled as random with normal distribution; others were 
treated as fixed effects.
The slope (ki) is the excretion rate constant, and the mean 
value of ki derived from the model was converted to half-life 
(ln2/mean(ki)). The values of ki were predicted using the best 
linear unbiased prediction method.10 To examine the variability 
of the half-life, the predicted ki values were converted to half-
lives. A small number of observations were however excluded, 
with negative values (apparently increasing serum levels) or 
extremely high half-life (with minimal ki). Summary half-life 
values have been presented as either a mean half-life (calculated 
from the mean elimination rate constant k) or as median half-life 
(the median value of the individually modelled half-life values). 
The 95% CI for mean(ki) from the regression was used to derive 
the CI for the half-life, by converting as for the mean.
The analyses were repeated for the age group 15–50 (at the 
start), stratified by gender. An interaction term for gender and 
excretion rate constant was used to test the significance of a sex 
difference in excretion rate.
The general background exposure was not subtracted when 
modelling the half-life, since the PFAS levels of the last sample 
for all the individuals were far above what is expected in the 
background.
RESuLTS
Serum levels at baseline
The median serum level of PFHxS was 180 times higher in the 
investigated Ronneby population compared with the referents 
from a neighbouring municipality, 42 times higher for PFOS 
and 6 times higher for PFOA (table 3). In the main Ronneby 
study group 98% of the 3418 participants had PFHxS levels over 
the 90th centile (2.58 ng/mL) of PFHxS levels observed in the 
Karlshamn group. A similar pattern was seen for PFOS, where 
90% of the main Ronneby group had levels in excess of the 90th 
centile (9.85 ng/mL) in the Karlshamn group, and PFOA, where 
85% of the main Ronneby group had levels in excess of the 90th 
centile (2.91 ng/mL).
The participants in the panel study initially had serum levels of 
PFHxS, PFOS and PFOA that were somewhat higher than in the 
main Ronneby study population. This difference reflected the 
fact that the main population, but not the panel group, included 
persons living in the non-exposed area of Ronneby. The base-
line serum levels in the panel study group ranged from 12.3 to 
1660 ng/mL for PFHxS, 24.1 to 1500 ng/mL for PFOS, and 2.38 
to 92 ng/mL for PFOA (table 3).
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Table 4 Excretion rate and half-lives for serum PFAS concentrations in 106 participants in a panel study after end of exposure through 
contaminated drinking water
All Men aged 15–50 Women aged 15–50
Mean 95% CI Mean 95% CI Mean 95% CI p*
Excretion rate constant (per year)†
PFHxS 0.13 0.12 to 0.15 0.09 0.07 to 0.11 0.15 0.12 to 0.18 0.008
PFOS 0.20 0.19 to 0.22 0.15 0.11 to 0.18 0.22 0.19 to 0.26 0.004
PFOA 0.26 0.24 to 0.28 0.25 0.19 to 0.26 0.29 0.23 to 0.34 0.29
Half-life (years)‡
PFHxS 5.3 4.6 to 6.0 7.4 6.0 to 9.7 4.7 3.9 to 5.9 0.008
PFOS 3.4 3.1 to 3.7 4.6 3.7 to 6.1 3.1 2.7 to 3.7 0.004
PFOA 2.7 2.5 to 2.9 2.8 2.4 to 3.4 2.4 2.0 to 3.0 0.29
The subgroup aged 15–50 includes 20 men and 30 women.
*p Values for the difference between genders in the model for excretion rate.
†The estimates in the table are adjusted for age, gender and body mass index in a mixed-effects model.
‡Half-life values are all calculated from excretion rate constant.
PFAS, perfluorinated and polyfluorinated substance; PFHxS, perfluorohexane sulfonate; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate.
Figure 1 The interindividual variation of half-lives for perfluorinated 
and polyfluorinated substances in 106 participants in a panel study after 
end of exposure through contaminated drinking water, excluding outliers. 
PFHxS, perfluorohexane sulfonate; PFOA, perfluorooctanoate; PFOS, 
perfluorooctane sulfonate. 
Exposure assessment
Age at baseline had a strong effect on serum PFHxS, PFOS 
and PFOA concentrations with average increases of 1.5%, 1.4% 
and 1.1% per year of age, respectively. Gender and BMI were 
not associated with any of the PFAS at baseline.
decline of serum levels during follow-up
The average decreases in serum level were for PFHxS 25%, for 
PFOS 35% and for PFOA 38% from June 2014 to September 
2016.
Table 4 shows the results for each excretion rate constant and 
the corresponding half-life in models for each PFAS. The mean 
excretion rate constant for PFHxS was 0.13, which is the annual 
change in log concentration, equivalent to the concentration of 
PFHxS in serum reducing by 13% per year since clear water was 
provided. This excretion rate constant is equivalent to a mean 
half-life of 5.3 (95% CI 4.6 to 6.0) years. For PFOS, the annual 
decrease was 20%, and the mean half-life was 3.4 years (95% CI 
3.1 to 3.7 years). The average decrease in PFOA was 26% of its 
previous value each year, corresponding to a mean half-life of 
2.7 years (95% CI 2.5 to 2.9 years).
The distributions of half-lives are shown in figure 1, after 
exclusion of outliers for the fitted estimated half-life as follows: 
one with a negative half-life (n=1 for PFHxS) and nine over 10 
years (n=8 for PFHxS, n=1 for PFOS). The median value of the 
remaining half-lives for PFHxS was 5.5 years (5%–95% range: 
3.0–9.2 years). For PFOS, the median half-life was 3.5 years 
(5%–95% range: 2.2–6.2 years). For PFOA, the median half-life 
for PFOA was 2.7 years (5%–95% range: 1.8–5.1 years).
Women aged 15–50 had a considerably shorter mean half-
life for PFHxS compared with men (table 3), with men 1.6-fold 
longer. For PFOS the pattern was similar, with men 1.5-fold 
longer. For PFOA the difference was small. The distributions 
of half-lives in women and men aged 15–50 are illustrated in 
online supplementary figure S1.
dISCuSSIOn
Among 106 persons observed between 6 and 33 months after 
end of exposure to PFAS-contaminated drinking water, the 
shortest half-life was observed for PFOA with a mean of 2.7 
years. The half-life for PFHxS was twice as long, 5.3 years, and 
for PFOS the mean was 3.4 years. These results are somewhat 
shorter than the prior results for PFOS and PFHxS, based on 
observations in 24 retired fluorocarbon workers, to our knowl-
edge the only other study that hitherto has reported apparent 
half-lives for PFOS and PFHxS after end of exposure that was 
substantially higher than the general population background.4 
The retired workers, all but two men, were older than our 
population, had higher serum levels of PFOA and PFOS, and 
were followed for a longer period, 5 years. For PFHxS, the 
apparent half-life has been estimated to be 15.5 years in a recent 
study from a community with residential exposure to PFAS.11 
The PFHxS levels in serum in that study were much lower than 
in our study, that is, 6.4 ng/mL vs 152 ng/mL. Furthermore, 
their population still had ongoing exposure, and a pharma-
cokinetic modelling approach based only on water intake was 
used to account for ongoing exposure. In our study, the back-
ground exposure was not subtracted when modelling half-life 
since the exposure levels in the general population from all 
sources were negligible compared with earlier drinking water 
intake in the study population. Our estimate of apparent half-
life, which was obtained after a documented abrupt end of the 
dominating source of exposure, is thus a reliable estimate of 
the actual half-life of PFHxS.
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Our estimate of apparent half-life for PFOA is in the range 
of values reported from five studies with averages ranging from 
2.3 to 3.94 years, observed in fluorocarbon workers4; studies in 
populations living in PFOA-polluted areas around production 
plants, followed for 1–2 years after provision of clean drinking 
water5 12; occupationally exposed ski waxers13; and a study in 
a community exposed residentially to PFAS.11 For PFOS, the 
population half-life has been estimated to be 4.3 years from 
studies in US blood donors reflecting general population reduc-
tion in exposure.14 After an abrupt end of a dominating source 
of exposure, as in Ronneby, the finding of a shorter apparent 
half-life is as expected.
The interindividual variation in half-life was substantial, 
with a threefold difference between the 5th and 95th percen-
tiles in each of the three PFAS, plus a few extreme outliers 
with extremely long half-lives. Large interindividual differ-
ences were also observed in retired fluorocarbon workers4 and 
in the general population after end of drinking water expo-
sure.5 12 The variability between individuals, and between men 
and women, has not yet been adequately explained.
Blood loss due to menstruation accounts partly for a shorter 
elimination half-life in women, and was estimated to account 
for 30% of the discrepancy in elimination of PFOS between 
men and women.6 In this respect, the marked gender differ-
ence in elimination of PFHxS, as observed in our study and by 
Brede et al5 but not for PFOA (our study and Bartell et al12), 
with PFOS in between, is intriguing. Elimination pathways 
that are sex-specific and substance-specific appear to exist.
Reabsorption by OATs in the kidneys and extensive uptake 
from enterohepatic circulation for PFOS and PFOA are active 
processes that may differ between individuals, but also between 
different PFASs. An increased renal PFAS elimination at high 
doses indicates a capacity-limited, saturable renal resorp-
tion process via high-efficiency OATs,15 16 which may have 
sex-different expression.17 Moreover, in a PFOA-exposed US 
population, the excretion rate was related to polymorphisms 
(single-nucleotide polymorphisms; SNPs) in tubular transporter 
proteins.18 Faecal elimination is little studied in humans, with the 
exception of some case reports that indicate that cholestyramine, 
a lipid-lowering pharmaceutical, may enhance elimination.19
In addition to differences between individuals as to excre-
tion capacity, recent data using paired human serum and urine 
samples for estimation of T½ have indicated marked differ-
ences between excretion of PFASs with different chain-length 
and isomers.20 It is likely that linear isomers are preferentially 
retained,21 but observational longitudinal human data on the 
excretion of linear versus branched chain isomers are absent. 
Thus, variation of T½ between populations and between indi-
viduals using total PFOS, PFOA and PFHxS determinations (as 
in this study) may in part reflect body burdens with different 
isomer composition.
Such differences are likely to be found in humans, given the 
varying production methods of PFAS over time. Synthesis of 
PFAS is by electrochemical fluorination or fluorotelomerisa-
tion. Electrochemical fluorination was used from the 1950s 
until the early 2000s and yielded branched and linear isomers. 
By contrast, fluorotelomerisation, which was later introduced, 
produces almost exclusively linear compounds.22 The fire-
fighting foams used over time have differed in composition, 
but there may also be varying fate of different PFAS struc-
tural isomers during soil and groundwater transportation. 
Thus, it is of importance to include determination of both 
linear and branched isomers of PFOS, PFHxS and PFOA 
in order to understand differences in observed half-lives. 
Refined estimates of the half-lives of PFAS compounds and the 
important denominators of variance are needed to reconstruct 
historical exposure for epidemiological studies as well as to 
project future exposures for risk assessment.
Out of the hundreds of PFAS compounds now available, only 
PFOS is internationally regulated according to the Stockholm 
Convention, and PFOA is on the candidate list. The human data 
on PFHxS uptake and elimination are hitherto very limited. 
The present observations confirm the long persistence of this 
compound after end of external exposure—a rough extrapo-
lation based on the mean half-life indicates that 10-year-old 
children from the contaminated water district cannot expect 
to attain the same PFHxS levels as their peers in the neigh-
bouring town of Karlshamn until the age of 60–70. Thus, even 
after prompt end of external exposure, AFFF contamination 
of drinking water can result in very high exposure levels in 
a life-course perspective in local general populations. Hence, 
the need for precautionary regulations for classes of PFASs is 
imperative.
Limitation
The main limitation of the present first analysis is that the 
serum samples were analysed during a 2-year period and each 
individual’s samples were not analysed in the same batch. All 
samples were analysed at the same laboratory with the same 
methods and work-up procedure. However, there is a need to 
reanalyse all samples from each individual in the same batch 
to reduce laboratory variation, especially when determinants 
for variation in half-lives are investigated. This is planned as a 
next step in our studies.
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